 |
|
Potential prostate cancer treatment improvements discovered by researchers at Cedars-Sinai
March 22, 2006Raloxifene, drug used for osteoporosis, shown to potentially benefit prostate cancer patients
In a study to be published in the April, 2006 issue of the British Journal of Urology International, researchers at Cedars-Sinai Medical Center have shown that Raloxifene, a drug commonly used to treat osteoporosis, has a potential clinical benefit in treating men with prostate cancer. This study has implications for the approximately 35,000 men who will die this year of advanced prostate cancer.
Prostate cancer is the leading cause of cancer and the second leading cause of cancer-related death among men living in the United States. Approximately one in six men will be diagnosed with prostate cancer during his lifetime. "We undertook this study because we desperately need new therapies for patients with advanced prostate cancer," said David B. Agus, M.D., research director of the Louis Warschaw Prostate Cancer Center at Cedars-Sinai and principal investigator of the study.
Since Raloxifene is a drug already on the market, researchers were able to move directly into a Phase II clinical trial. They identified the presence of the beta isoform of the estrogen receptor in prostate cancer tissue samples, then moved directly into studies of animals with human prostate cancer, and then onto human clinical trials. The entire process took only 2-3 years.
"It used to be that to show effectiveness through research studies, cancer drugs needed to shrink tumors by 50 percent," Agus said. "Now, the new way of thinking about the effectiveness of cancer drugs is whether they can slow cancer's growth, which ultimately may significantly benefit patients."
Through the study, patients were given a daily oral dosage of Raloxifene, and the disease and its symptoms were followed on a regular basis. Some of the patients in the clinical trial taking Raloxifene showed evidence of disease stabilization manifested by a slowing or stopping of the growth of their prostate cancer.
According to Ronald L. Shazer, M.D., primary author of the manuscript, "The outcome from the Phase II clinical trial merits further study in a randomized clinical trial to demonstrate the clinical benefit of this targeted therapy."
Cedars-Sinai Medical Center
Since Raloxifene is a drug already on the market, researchers were able to move directly into a Phase II clinical trial. They identified the presence of the beta isoform of the estrogen receptor in prostate cancer tissue samples, then moved directly into studies of animals with human prostate cancer, and then onto human clinical trials. The entire process took only 2-3 years.
"It used to be that to show effectiveness through research studies, cancer drugs needed to shrink tumors by 50 percent," Agus said. "Now, the new way of thinking about the effectiveness of cancer drugs is whether they can slow cancer's growth, which ultimately may significantly benefit patients."
Through the study, patients were given a daily oral dosage of Raloxifene, and the disease and its symptoms were followed on a regular basis. Some of the patients in the clinical trial taking Raloxifene showed evidence of disease stabilization manifested by a slowing or stopping of the growth of their prostate cancer.
According to Ronald L. Shazer, M.D., primary author of the manuscript, "The outcome from the Phase II clinical trial merits further study in a randomized clinical trial to demonstrate the clinical benefit of this targeted therapy."
Cedars-Sinai Medical Center
Prostate Cancer Treatment Current Events and Prostate Cancer Treatment News RSSNew Approach for Treating Recurrent Prostate Cancer on the Horizon
A new study shows that an alpha-particle emitting radiopeptide-radioactive material bound to a synthetic peptide, a component of protein-is effective for treating prostate cancer in mice.
Long-term study shows low oxygen levels in prostate tumors can predict recurrence
Fox Chase Cancer Center researchers have discovered that low-oxygen regions in prostate tumors can be used to predict a rise in prostate-specific antigen (PSA) levels, a marker of tumor recurrence in prostate cancer.
Molecular fingerprints point the way to earlier cancer diagnosis and more targeted treatment
Metabolites are molecular fingerprints of what your cells are up to and Dr. Arun Sreekumar wants to know the impression made by cancer.
U.S. trial shows no early mortality benefit from annual prostate cancer screening
The prostate cancer screening tests that have become an annual ritual for many men don't appear to reduce deaths from the disease among those with a limited life-expectancy, according to early results of a major U.S. study involving 75,000 men.
Prostate cancer spurs new nerves
Prostate cancer - and perhaps other cancers - promotes the growth of new nerves and the branching axons that carry their messages, a finding associated with more aggressive tumors, said researchers from Baylor College of Medicine in the first report of the phenomenon that appears today in the journal Clinical Cancer Research.
OHSU Cancer Institute researchers study breathing during radiation
Oregon Health & Science University researchers have determined exactly how much breathing affects prostate movement during radiation treatment.
MR imaging accurately determines prostate cancer treatment failure
Dynamic contrast-enhanced MRI (DCE-MRI) plus diffusion weighted imaging (DWI) can accurately diagnose residual or recurrent prostate cancer in patients treated with high-intensity focused ultrasonic ablation, a new study shows.
Prostate size and other neglected factors influence prostate cancer treatment satisfaction
Men with prostate cancer and their partners face difficult decisions regarding treatment, and accurate information regarding expected outcomes can be hard to find, according to results of a multi-center study published Wednesday in the New England Journal of Medicine.
'Mismatched' prostate cancer treatment more common than expected
More than a third of men with early prostate cancer who participated in a study analyzing treatment choice received therapies that might not be appropriate, based on pre-existing problems with urinary, bowel or sexual function.
Standard treatment for prostate cancer may encourage spread of disease
A popular prostate cancer treatment called androgen deprivation therapy may encourage prostate cancer cells to produce a protein that makes them more likely to spread throughout the body, a new study by Johns Hopkins researchers suggests.
More Prostate Cancer Treatment Current Events and Prostate Cancer Treatment News Articles
 |
The Prostate Cancer Treatment Book by Peter Grimm (Author), John Blasko (Author), John Sylvester (Author) The latest and most progressive treatment advice from prostate cancer experts at the nation's top medical centers For each of the nearly 200,000 Americans diagnosed with prostate cancer annually, the months following the diagnosis are a time of momentous decisions and enormous emotional strain. This book offers readers complete answers to all their questions about the best treatment options for fighting and beating prostate cancer. Bringing together the insights and expertise of 21 of the nation's top prostate cancer specialists from the Mayo Clinic, Harvard Medical School, Memorial Sloan-Kettering, the Seattle Prostate Institute, and other leading treatment centers, The Prostate Cancer Treatment Book provides: Expert information on all treatment options, including... |
 |
Botanic Choice Saw Palmetto (Pack of 4) by Botanic Choice Now you can get double the benefits for your prostate with this dynamic duo. Whether you’re 25 or 85, Saw Palmetto and Pygeum could give your health the boost you need. What makes Botanic Choice's blend unique is that both ingredients are standardized. Pygeum Africanum Extract has been standardized for 6.5% phytosterois and Saw Palmetto Extract has been standardized for 25% fatty acids. Get maximum prostate protection today! |
 |
Prostate Cancer: Prevention, Diagnosis, and Treatment Prostate cancer is the most commonly diagnosed cancer in men in the United States. Virtually every man over 40 has cancerous growths in his prostate, although most will not die of the disease. This program focuses on what is known about preventing prostate cancer, current diagnostic techniques, and the variety of treatments available. James D. Brooks, MD, is Assistant Professor of Urology at the Stanford University School of Medicine. Dr. Brooks focuses exclusively on the treatment of prostate cancer. He is an acknowledged expert in the technique of nerve-sparing radical retropubic prostatectomy and in the surgical anatomy of the pelvis, and has carried out pioneering research on the genetic changes occurring in urological cancers. He has also published extensively on scientific and... |
 |
You Can Beat Prostate Cancer by Robert J. Marckini (Author) The task of choosing the right prostate cancer treatment is daunting. It is further complicated by conflicting information the patient receives from physicians and the Internet. This book is written by a prostate cancer survivor who now runs an international prostate cancer support group. It's about his journey and the important things he learned along the way. It is the book the author wishes had been available when he was diagnosed 6 years ago. It is intended to provide specific information for men who are at risk or have been recently diagnosed with prostate cancer. All major treatment options are examined and the pros and cons of each are summarized. A relatively new, non-invasive, highly effective treatment is highlighted. It is an option that cures cancer as well as any other... |
 |
Prostate Cancer Meets The Proton Beam: A Patient's Experience by Fuller Jones (Author) Proton Beam Therapy is an advanced cancer treatment based on the elegant physics of the proton. It is not well known, because there are currently only five hospitals in the U.S. that have the expensive and complex equipment to administer it. Protons have been used for cancer treatment in the U. S. since 1990 with success comparable to all other options, but with minimal side effects. Proton therapy is Medicare and FDA approved, and may be used for prostate and other non-metastasized cancers. The book explains how to deal with the shock of cancer diagnosis and become an empowered patient. It includes a synopsis of the major treatment alternatives, and a detailed description of proton beam therapy. Robert J. Marckini, author of "You Can Beat Prostate Cancer..." says Prostate Cancer Meets... |
|
Radiation Treatments for Prostate Cancer Medical Straight Talk Series Also With: Dr Nagel (Primary Contributor) VHS mens health educational about prostate cancer | |
|
Save Your Life Collection ( 12 VHS Videos) by Save Your Life Videos, Inc. Save Your Life Collection: 12 video set. 1)Introduction, 2)Basic programs for curing people who are not supposed to live, 3)Breast Cancer, 4)Prostate Cancer, 5)Fast-Growing cancers, 6)Why most herbal products you buy belong in the trash, not in you mouth, 7) Infusions, fomentations, poultics, and ointments, 8)Making Tinctures: What you need to know to cure loved ones that doctors have sent home to die, 9)Bodywork: How to blow away blockages that keep herbs from getting to sick organs, 10)Water Treatments: just as powerful as herbs, skip them and you may die, 11)Serious mistakes that can stop your recovery, 12)Top questions from viewers on curing cancer at home. | |
 |
Conquer Prostate Cancer: How Medicine, Faith, Love and Sex Can Renew Your Life by Rabbi Edgar J. Weinsberg (Author), Dr. Robert I. Carey (Contributor) This inspiring physical, emotional, and spiritual guide empowers patients and survivors, including Boomers and Seniors, to face diagnosis with dignity, explore their options realistically, and tackle recovery with optimism and determination. "Rabbi Weinsberg draws on his own medical ordeal to bring guidance and comfort to others." -- Rabbi Harold Kushner, author of When Bad Things Happen to Good People |
 |
What Your Doctor May Not Tell You About(TM) Prostate Cancer: The Breakthrough Information and Treatments That Can Help Save Your Life (What Your Doctor May Not Tell You About...) by Glenn J. Bubley (Author), Winifred Conkling (Author) DESCRIPTION: An expert in the field offers new and potentially life- saving alternative treatments for the #1 health concern of men over 50: prostate cancer. |
 |
Prostate Cancer Demystified: NEW LIFE-SAVING PROSTATE CANCER TREATMENTS by Robert Bard (Author) Dr. Stamey, pioneer of PSA, says, ". . . that PSA now predicts only 2 percent of cancers," Urology, 2004. Biopsies underestimate cancer in 64.6% of men under age 65The Journal of Urology, 2005"Antioxidant therapies arrest 80% of prostate cancer," reports International Society of Endovascular Therapy, 2007-"Routine biopsies miss up to 78 percent of cancer," discussed at New York Roentgen Conference, 2005."...unproven screening test, the PSA blood test for prostate cancer." Journal of American College of Radiology, 2005"New non invasive treatments reduce impotence and incontinence"Prostate Cancer Research Institute, 2005"image guidance with MRI or ultrasound allows precise ablation oflesions of any shape without damage to surrounding structures"Radiology 2005"3% of prostate cancer is... |
| © 2009 BrightSurf.com |